Asbestosis or Mesothelioma is the most lethal cancer in men (with colorectal cancer and prostate cancer) and the second most deadly in women (after breast cancer and before colorectal cancer). It is generally between 50 and 65 years old, and smoking is implicated in 9 out of 10 cases.
37 deaths per 100,000 men
Specifically, the estimated mortality rate is 37 deaths per 100,000 men and 12.9 deaths per 100,000 women, with an estimated incidence of cancer of 51.7 per 100,000 men and 18.6 per 100,000 women. 100,000 women. In 2012, the National Cancer Institute (Inca) recorded 29,949 lung cancer deaths in metropolitan France, including 28,211 men and 11,284 women. Moreover, the average age of death in France is 66 years for men and 65 years for women.
The chances of survival depend on the stage of cancer
The chances of survival will depend on the stage at which the cancer is diagnosed. They will be higher if the cancer is detected at an early stage (stage 1 or 2) and will decrease if it is only discovered at stages 3 or 4, which means that the cancer has spread in the form of metastases to lymph nodes, pleura, other lung or other organs outside the thorax. Thus, according to the Inca, which relies on the results of the national PETRI study, the 5-year relative survival is 47% for a stage 1 diagnosis, 32% for stage 2, 22% for stage 3 and only 5% for stage 4. This means, for example, that a person diagnosed with stage 1 lung cancer will have a 47% chance of being alive 5 years after diagnosis.
Prognosis and survival for lung cancer
If you have lung cancer, you may have questions about your prognosis. A prognosis is the act by which the doctor best assesses how cancer will affect a person and how they will respond to treatment. Prognosis and survival depend on many factors. Only a doctor who is familiar with your medical history, the type of cancer you have, the stage and other characteristics of the disease, the treatments chosen, and the response to treatment can examine all of these data in conjunction with survival statistics. to arrive at a prognosis.
A prognostic factor is an aspect of the cancer or a characteristic of the person (such as his overall state of health) that the physician considers when making a prognosis. A predictor influences the way cancer responds to a certain treatment. Prognostic factors and predictive factors are often discussed together, and both play a role in the choice of treatment plan and prognosis.
The following are prognostic or predictive factors for lung cancer.
Stage is the most important prognostic factor for lung cancer. Early stages give a better prognosis than advanced stages.
Stages 0 and 1 of non-small cell lung cancer generally have a more favorable prognosis than stages 2, 3 or 4. Limited-stage small-cell lung cancer has a much better prognosis than extended-stage cancer.
Number and types of metastases
People with lung cancer who have only one metastasis have a better prognosis than those with multiple metastatic tumors. A metastasis unique to the brain can lead to a more favorable prognosis than multiple metastases in another part of the body.
Non-small cell lung cancer that has spread to the adrenal glands has a better prognosis than cancer that has spread to the brain or liver.
Small cell lung cancer that has spread to the brain has a less favorable prognosis than a cancer that has spread only to the bones or the mediastinum.
A person who has lost more than 5% of his body weight before treatment has a less favorable prognosis than a person who has not lost a lot of weight.
The functional index is a measure of a person's ability to perform daily activities and routine tasks. People with a high functional index have a better prognosis than those with a low index.
The woman with lung cancer has a prognosis a little more encouraging than a man with the same disease.
A person who has lung problems has a less favorable prognosis. The pulmonary disorders can be these:
- Collapse of a lung
- Pulmonary infection (pneumonia)
- Accumulation of fluid around the lung (pleural effusion)
During the diagnostic process, several lung cancer tissue assays are performed to determine whether the cancer cell genes exhibit certain changes (mutations). These markers can predict to what extent non-small cell lung cancer could respond to specific treatments.
The epidermal growth factor receptor positive tumor (R-EGF) has too many R-EGF receptors. This cancer will react to drugs that block these receptors. Anaplastic lymphoma kinase (ALK) is a gene that is mutated in a very small number of non-small cell lung cancers. The ALK-positive tumor reacts to drugs that block the signals that are transmitted by the ALK mutation. BRAF is a gene that controls cell signaling and growth. BRAF V600 mutations are observed in a very small number of non-small cell lung cancers. BRAF V600 positive tumors respond to drugs that interrupt the signals of BRAF V600 mutations.